These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 16477242)

  • 21. Bullous lesions at polyethylene glycol interferon-alpha-2a inoculation site in a hepatitis C virus-infected subject.
    Montesu MA; Siddi V; Satta R; Pirodda C; Cottoni F
    Acta Derm Venereol; 2007; 87(5):433-4. PubMed ID: 17721655
    [No Abstract]   [Full Text] [Related]  

  • 22. Practical management of liver transplant recipients for hepatitis C.
    Saab S; Busuttil RW
    Minerva Chir; 2003 Aug; 58(4):479-89. PubMed ID: 14603160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fulminant autoimmune hepatitis after successful interferon treatment in an HIV-HCV co-infected patient.
    Coriat R; Podevin P
    Int J STD AIDS; 2008 Mar; 19(3):208-10. PubMed ID: 18397566
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Controversies in the management of hepatitis C virus infection after liver transplantation.
    Shiffman ML; Vargas HE; Everson GT
    Liver Transpl; 2003 Nov; 9(11):1129-44. PubMed ID: 14586872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mooren's ulcerative keratitis after systemic pegylated interferon alpha2a in chronic hepatitis C.
    Yeo JH; Kim KW; Kim JC
    Can J Ophthalmol; 2017 Oct; 52(5):e163-e167. PubMed ID: 28985822
    [No Abstract]   [Full Text] [Related]  

  • 26. Cryptosporidiosis in a patient on PEG-interferon and ribavirin for recurrent hepatitis C after living donor liver transplantation.
    Manz M; Steuerwald M
    Transpl Infect Dis; 2007 Mar; 9(1):60-1. PubMed ID: 17313476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adverse response to pegylated interferon therapy in two patients with chronic hepatitis C.
    Thomas WL; Ramos F; Hospenthal DR
    Hawaii Med J; 2003 Aug; 62(8):163-4. PubMed ID: 14533347
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Fatal Outcome for subcutaneous administration of Pegylated IFN alpha 2b in a man with Chronic C hepatitis under treatment with traditional bitherapy].
    Domínguez Gozalo A; Hidalgo Correas FJ; García Benayas E; García Díaz B
    Farm Hosp; 2015 May; 39(3):186-8. PubMed ID: 26005896
    [No Abstract]   [Full Text] [Related]  

  • 29. Impact of pegylated interferon alfa-2a and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series.
    Mukherjee S; Lyden E
    Hepatogastroenterology; 2006; 53(70):561-5. PubMed ID: 16995462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation.
    Thomas RM; Brems JJ; Guzman-Hartman G; Yong S; Cavaliere P; Van Thiel DH
    Liver Transpl; 2003 Sep; 9(9):905-15. PubMed ID: 12942451
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cutaneous necrosis complicating the injection of pegylated interferon alpha-2b in a patient with chronic hepatitis C.
    Rosina P; Girolomoni G
    Acta Dermatovenerol Croat; 2008; 16(1):35-7. PubMed ID: 18358108
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute pancreatitis attributed to the use of pegylated interferon in a patient with chronic hepatitis C.
    Tahan V; Tahan G; Dane F; Uraz S; Yardim M
    J Gastrointestin Liver Dis; 2007 Jun; 16(2):224-5. PubMed ID: 17592576
    [No Abstract]   [Full Text] [Related]  

  • 33. [Treatment of cirrhotics].
    Galdame O; Jorge A; Sordá J
    Acta Gastroenterol Latinoam; 2005 Jun; 35 Suppl 1():S42-5. PubMed ID: 20214300
    [No Abstract]   [Full Text] [Related]  

  • 34. Effectiveness and safety of everolimus in the treatment of autoimmune hepatitis related to anti-hepatitis C virus therapy after liver transplant: three case reports.
    Casanovas T; Argudo A; Peña-Cala MC
    Transplant Proc; 2011; 43(6):2233-6. PubMed ID: 21839242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Skin necrosis after injection of PEG-interferon alpha2b in an HCV-infected patient.
    Sparsa A; Loustaud-Ratti V; Alain S; Liozon E; Bédane C; Vidal E
    Acta Derm Venereol; 2004; 84(5):415-6. PubMed ID: 15503367
    [No Abstract]   [Full Text] [Related]  

  • 36. Plasma ribavirin concentrations during treatment of recurrent hepatitis C with peginterferon alpha-2b and ribavirin combination after liver transplantation.
    Dumortier J; Ducos E; Scoazec JY; Chevallier P; Boillot O; Gagnieu MC
    J Viral Hepat; 2006 Aug; 13(8):538-43. PubMed ID: 16901284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of recurrent hepatitis C virus infection after liver transplantation].
    Lengyel G; Tulassay Z
    Orv Hetil; 2007 Oct; 148(40):1875-81. PubMed ID: 17905682
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment of hepatitis C in patients on renal replacement therapy].
    Tornai I; Mátyus J
    Orv Hetil; 2007 Mar; 148(11):489-94. PubMed ID: 17350920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antimitochondrial antibody serocoversion post-liver transplant during hepatitis C treatment with peginterferon α, ribavirin and telaprevir.
    Marquez-Azalgara V; Hussaini T; Erb SR; Yoshida EM
    Ann Hepatol; 2014; 13(5):565-7. PubMed ID: 25152991
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fibrosis progression in hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (interferon-ribavirin therapy).
    Bahra M; Neumann UP; Jacob D; Langrehr JM; Berg T; Neuhaus R; Neuhaus P
    Transplantation; 2007 Feb; 83(3):351-3. PubMed ID: 17297412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.